The first data has emerged on the uptake of Novo Nordisk's new oral version of GLP-1 agonist weight-loss therapy Wegovy, with encouraging signs of strong demand as a potential rival from Eli Lilly ...
Measure who they know, not just who they are. by Paul Leonardi and Noshir Contractor “We have charts and graphs to back us up. So f*** off.” New hires in Google’s people analytics department began ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results